Edgar Engleman, M.D. is a founding member and Chief Scientific Advisor of Vivo Capital. Dr. Engleman is Professor of Pathology and Medicine at the Stanford University School of Medicine, where he established and oversees the Stanford Blood Center, directs his immunology research team, and co-directs the Tumor Immunotherapy Program of the Stanford Cancer Institute. He is an inventor of multiple patented technologies, has authored more than 350 publications in medical and scientific journals, and trained more than 100 graduate and postgraduate students. Dr. Engleman is the lead inventor of the technology underlying a cancer immunotherapy known as Provenge (Sipulucel-T), which was shown to extend the life of patients who suffer from metastatic prostate cancer. Provenge is the first in the class of personalized immunotherapeutic agents to be FDA approved for the treatment of cancer. He is also the lead inventor of the technology underlying the immunotherapies in development at Bolt Biotherapeutics.
Dr. Engleman is the founder or cofounder of a number of biotech companies including Cetus Immune (acquired by Novartis), Genelabs (acquired by GlaxoSmithKline), Dendreon (acquired by Sanpower) and Bolt. He currently serves on the boards of Bolt (BOLT) and several private companies. He previously served on the boards of Soleno (SLNO), REGENEXBIO (RGNX), Eiger (EIGR), , Intermune (ITMN, acquired by Roche), Insmed (INSM), Prestwick (acquired by Biovail) and Semnur (acquired by Sorrento (SRNE).
He received his BA from Harvard College and earned his M.D. from Columbia University School of Medicine. In 2017, he received the CABS K Fong Prize for achievements in life sciences, and in 2022 he received the Columbia University Gold Medical for Outstanding Achievement in Medical Research.